skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Daniel

+9 year(s) experience

Daniel Chancellor - Pharmaintelligence
Director Daniel Chancellor analyzes and forecasts drug markets for neurology, psychiatry, and rare diseases.

He stays abreast of market developments, generating and curating data sources, and distilling these into reports that enable clients to gain a competitive edge.

Since joining Pharma Intelligence in 2010, Daniel has tracked and forecast all the leading neurology, psychiatry, and pain drug markets. He is particularly interested in the shifting landscape of the multiple sclerosis market well as the implications of trial failures – alongside the successes in Alzheimer's disease R&D.

He has helped expand research and insight on rare diseases , including established orphan drug markets as well as as emerging opportunities. He also attends international medical conferences and enjoys collaborating with colleagues at Scrip.

Daniel has a First Class degree in Natural Sciences from the University of Bath.


Analyst Articles

Articles by Ian

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharmaprojects 2018 Pharma R&D Infographic

    30 May 2019

    Will the Pharma R&D Annual Review 2018 from Citeline’s Pharmaprojects be music to your ears, or will it sound a sour note? Find out with the Pharma R&D Annual Review 2018 infographic, now available to you as a free download.

    Topic drug-development-landscape

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2019 Infographic

    12 Mar 2019

    Get your head in the game with a free download of the Pharma R&D Annual Review 2019 infographic from Informa Pharma Intelligence. This year’s look at the key players and reigning champs of R&D uses a sports theme to present its critical data on the current state of pharma R&D.

    Topic Research Drug development landscape Diseases Drug review

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2018

    15 May 2018

    Authored for the last 25 years by Ian Lloyd, Senior Director of Pharmaprojects and Data Integration, this vital resource uses a music motif to turn up the volume on the evolution of trends in pharmaceutical R&D. Lloyd assesses industry trends by examining the pipeline by company, therapeutic area, disease, target, and drug type.

    Topic research

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2018 Supplement

    10 Apr 2018

    You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects. Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.

    Topic drug-development-landscape

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2017

    By Ian Lloyd 22 Mar 2017

    Thank you for your interest in the latest report from Pharmaprojects, Pharma R&D Annual Review 2017.

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D By Numbers

    22 Mar 2017

    Welcome to Pharmaprojects' 2017 review of trends in pharmaceutical R&D.

    Topic drug-review deal-trends company-analysis

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharmaprojects Pharma RD Annual Review 2016

    01 Feb 2016

    For around a quarter of a century now, I've been taking an annual look at the continuing drama which is pharma R&D. Over the past 25 years, we've seen many a twist iand turn in the plot of this particular franchise, and here, we'll look at developments in a year which has seen some new players make the bit time, while others hit skid row after one too many negative (clinical) reviews. We'll see in which companies and diseases we are seeing The Force Awaken, and which are turning out to be merely a Phantom Menace. And we'll industry the types of drugs which are the rising starts and those which are garnering top billing.

    Topic Drug development landscape Drug review